Peramivir 'stop-work' order extension dents BioCryst
This article was originally published in Scrip
Executive Summary
BioCryst Pharmaceuticals investors were somewhat disheartened on 5 June after the company revealed that a so-called "stop-work order" from the Department of Health and Human Services (HHS) has been extended another 90 days to 5 September – with shares falling 4%.